Xiaoling Xu

6.9k total citations · 3 hit papers
85 papers, 4.2k citations indexed

About

Xiaoling Xu is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Xiaoling Xu has authored 85 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 22 papers in Molecular Biology and 19 papers in Oncology. Recurrent topics in Xiaoling Xu's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Lung Cancer Research Studies (10 papers). Xiaoling Xu is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Lung Cancer Research Studies (10 papers). Xiaoling Xu collaborates with scholars based in China, United States and Macao. Xiaoling Xu's co-authors include Haiming Wei, Yonggang Zhou, Binqing Fu, Xiaohu Zheng, Dongsheng Wang, Tiantian Li, Xiao‐Hua Zhang, Mingfeng Han, Wei Sun and Aijun Pan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Xiaoling Xu

72 papers receiving 4.1k citations

Hit Papers

Effective treatment of severe COVID-19 patients with toci... 2020 2026 2022 2024 2020 2020 2020 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effective treatment of severe COVID-19 patients with tocilizumab
    2020 1.9k citations Xiaoling Xu, Mingfeng Han et al. Proceedings of the National Academy of Sciences profile →
  2. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients
    2020 814 citations Yonggang Zhou, Binqing Fu et al. profile →
  3. Study of cardiovascular disease prediction model based on random forest in eastern China
    2020 232 citations Yang Li, Haibin Wu et al. Scientific Reports profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaoling Xu China 20 2.2k 1.3k 854 553 525 85 4.2k
Jianhua Mao China 24 1.5k 0.7× 834 0.6× 1.0k 1.2× 573 1.0× 317 0.6× 184 4.1k
Xiang Xie China 25 1.5k 0.7× 889 0.7× 831 1.0× 261 0.5× 502 1.0× 186 4.6k
Vincent W. Li United States 13 2.5k 1.1× 1.4k 1.1× 705 0.8× 680 1.2× 730 1.4× 26 4.3k
Jing Wan China 19 2.3k 1.0× 1.4k 1.1× 469 0.5× 268 0.5× 664 1.3× 45 4.0k
Shusheng Li China 20 3.0k 1.3× 1.8k 1.3× 647 0.8× 344 0.6× 552 1.1× 78 4.6k
Zuojiong Gong China 30 1.0k 0.5× 485 0.4× 1.1k 1.3× 282 0.5× 495 0.9× 130 4.0k
Qiu Zhao China 31 2.3k 1.0× 1.2k 0.9× 1.2k 1.4× 1.0k 1.8× 1.1k 2.0× 102 5.1k
Yiming Li China 22 1.0k 0.5× 505 0.4× 517 0.6× 346 0.6× 269 0.5× 74 2.8k

Countries citing papers authored by Xiaoling Xu

Since Specialization
Citations

This map shows the geographic impact of Xiaoling Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoling Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoling Xu more than expected).

Fields of papers citing papers by Xiaoling Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoling Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoling Xu. The network helps show where Xiaoling Xu may publish in the future.

Co-authorship network of co-authors of Xiaoling Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoling Xu. A scholar is included among the top collaborators of Xiaoling Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoling Xu. Xiaoling Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zheng, Bo, Muhammad Shahzaib, Zhifu Mi, et al.. (2025). Electron beam irradiation significantly improves post-harvest fruit quality and shelf-life of Mango (Mangifera indica L.). Postharvest Biology and Technology. 228. 113647–113647. 3 indexed citations
2.
3.
Li, Junyi, et al.. (2025). Study on the characteristics of bird communities in urban river corridor parks and green spaces. Environment Development and Sustainability.
4.
Liang, Zhen, Yanping Wang, Yu Zhou, et al.. (2024). Engineered ADSCs and doxycycline encapsulated antibacterial, immunomodulatory and proangiogenic hydrogels for infected burn wound healing. Chemical Engineering Journal. 503. 158478–158478. 9 indexed citations
5.
Xu, Xiaoling, Ding Wang, Weizhen Xu, et al.. (2024). NIPBL-mediated RAD21 facilitates tumorigenicity by the PI3K pathway in non-small-cell lung cancer. Communications Biology. 7(1). 206–206. 2 indexed citations
6.
Yuan, Ping, Jun Chen, Shang Wang, et al.. (2024). Impact of different sequential triple oral combination therapies based selexipag on outcomes in pulmonary arterial hypertension. Clinical Cardiology. 47(2). 1 indexed citations
7.
Xu, Xiaoling, Huihui Li, Mingying Xie, et al.. (2023). LncRNAs and related molecular basis in malignant pleural mesothelioma: Challenges and potential. Critical Reviews in Oncology/Hematology. 186. 104012–104012. 4 indexed citations
8.
9.
Zhang, Junli, Peng Lan, Changming Yang, et al.. (2021). Secondary bloodstream infection in critically ill patients with COVID-19. Journal of International Medical Research. 49(12). 3619123711–3619123711. 7 indexed citations
10.
Cai, Lei, Jiangfeng Wang, Junrong Yan, et al.. (2021). Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma. Frontiers in Oncology. 10. 603671–603671. 11 indexed citations
11.
Xu, Xiaoling, Ding Wang, Wei Wu, & Hongyang Lu. (2021). Molecular Characteristics of Genes and the Immune Microenvironment of a Rare Chest Malignant Tumor (Pulmonary Clear Cell Sarcoma): A Case Report. Frontiers in Oncology. 11. 664883–664883. 1 indexed citations
12.
Xu, Xiaoling, Na Li, Ding Wang, Wei Chen, & Yun Fan. (2021). Clinical Relevance of PD-L1 Expression and CD8+ T Cells’ Infiltration in Patients With Lung Invasive Mucinous Adenocarcinoma. Frontiers in Oncology. 11. 683432–683432. 12 indexed citations
13.
Xu, Xiaoling, Mingfeng Han, Tiantian Li, et al.. (2020). Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences. 117(20). 10970–10975. 1874 indexed citations breakdown →
14.
Li, Yang, Haibin Wu, Xiaoqing Jin, et al.. (2020). Study of cardiovascular disease prediction model based on random forest in eastern China. Scientific Reports. 10(1). 5245–5245. 232 indexed citations breakdown →
15.
16.
Zhang, Ruifeng, Guofeng Ma, Xiaoling Xu, & Liang Li. (2018). Percutaneous treatment for silicosis-induced pulmonary artery stenosis. Medicine. 97(2). e9469–e9469. 7 indexed citations
17.
Mao, Weimin, Lei Tao, Xiaoling Xu, Wei Chen, & Yaping Xu. (2016). Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer. OncoTargets and Therapy. 9. 921–921. 7 indexed citations
18.
19.
Wang, Xiaohua, Chao Yan, Xiaoling Xu, et al.. (2015). Long noncoding RNA expression profiles of hypoxic pulmonary hypertension rat model. Gene. 579(1). 23–28. 23 indexed citations
20.
Xu, Xiaoling, et al.. (2013). High-risk human papillomavirus infection among rural women of Jing'an County in Jiangxi Province:a cross-sectional study. 40(18). 1102–1105. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jianhua Mao Breakdown of academic impact, for papers by Xiang Xie Breakdown of academic impact, for papers by Vincent W. Li Breakdown of academic impact, for papers by Jing Wan Breakdown of academic impact, for papers by Shusheng Li Breakdown of academic impact, for papers by Zuojiong Gong Breakdown of academic impact, for papers by Qiu Zhao Breakdown of academic impact, for papers by Yiming Li
Rankless by CCL
2026